EP2528593A2 - Effervescent formulations comprising cefprozil as active agent - Google Patents

Effervescent formulations comprising cefprozil as active agent

Info

Publication number
EP2528593A2
EP2528593A2 EP11708946A EP11708946A EP2528593A2 EP 2528593 A2 EP2528593 A2 EP 2528593A2 EP 11708946 A EP11708946 A EP 11708946A EP 11708946 A EP11708946 A EP 11708946A EP 2528593 A2 EP2528593 A2 EP 2528593A2
Authority
EP
European Patent Office
Prior art keywords
cefprozil
sodium
acid
effervescent
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11708946A
Other languages
German (de)
French (fr)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bilgic Mahmut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2528593A2 publication Critical patent/EP2528593A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • Present invention relates to pharmaceutical formulations formulated in effervescent form comprising cefprozil active agent and the process for their preparation.
  • Cefprozil which is a second generation cephalosporin, was first disclosed in the patent numbered US4520022 and its chemical name is 8-[2-amino-2-(4-hydroxyphenyl)-acetyl] amino-7-oxo-4-prop-l-enyl-2-thia-6- azabicyclo [4.2.0]oct-4-ene-5-carboxylic acid.
  • Cefprozil shown with Formula 1 is indicated for use in treatment of bronchitis, ear infections, skin infections and for treatment of other infections.
  • the formulations comprising cefprozil as active agent are present in tablet, capsule or oral suspension forms.
  • the pharmaceutical formulations sold in the market under the tradename CEFZIL ® are present in tablet form comprising 250 and 500 mg cefprozil and in oral suspension form comprising 125 mg/5 ml and 250 mg/5 ml of cefprozil.
  • Tablet forms comprising 250 and 500 mg active agent in one dose become bigger in size when formulated with excipients. Accordingly, oral tablet and capsule dosage forms cause difficulty in swallowing especially for old people and children since they are difficult to swallow even though they are aclministered with water and have an unpleasant taste. This case impedes the drug intake and affects the efficacy of the treatment negatively. Moreover, bioavailability of oral dosage forms is far less than that of suspension forms.
  • suspension forms cause some problems such as; possibility to intake high and/or uncontrolled dose, the problems related to their physical and chemical stabilities after they are diluted with water and the difficulties in their usage and transferring.
  • new approaches are needed for obtaining formulations which are stable, which provides an efficient dosing and ease of use for especially pediatric and geriatric patients, which can disperse quickly and form a homogeneous suspension and have a high bioavailability.
  • the inventors have surprisingly found that the problems in the prior art can be solved by the effervescent formulations that are prepared in accordance with the present invention.
  • the present invention is related to effervescent formulations comprising cefprozil and process for the preparation of these formulations.
  • effervescent forms formulated with the formulation comprising 10-50% of cefprozil, 50-90 % of effervescent couple, 1-10% of binder and 1-15% of at least one pharmaceutically acceptable excipient with respect to the total weight of unit dose, homogeneously and quickly disperse in water, provide effective dosing and ease of use, appeal to a wider patient profile and are stable and highly bioavailable.
  • the first aspect of the present invention is effervescent formulations comprising 10-50% of cefprozil, 50-90% of effervescent couple, 1-10% of binder and 1-15% of at least one pharmaceutically acceptable excipient with respect to the total weight of unit dose.
  • effervescent formulations term used in the text comprises effervescent tablets, effervescent granules and effervescent powders.
  • effervescent formulations in accordance with the present invention are in the tablet form.
  • Effervescent powder, granule or tablet forms are more advantageous compared to the conventional forms due to the fact that they disperse quickly.
  • Effervescent formulations disperse quickly and simultaneously and they disperse the active agents into the aqueous medium. Therefore, drug provides a homogeneous suspension by quickly dispersing in water and the bioavailability of the active agent increases considerably.
  • the effervescent forms are more stable due to the fact that they are in solid form, they have a longer shelf-life compared to suspension forms. Effervescent dosage forms that are suitable for single dose usage provides a controlled dose intake.
  • Cefprozil that is used in the formulations formulated in effervescent form in accordance with the present invention can be present in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or as a combination thereof.
  • Cefprozil that is used in the present invention can be present in one of the forms of monohydrate, dihydrate, trihydrate and/or anhydrous. Preferably, it is present in the form of monohydrate.
  • Effervescent formulations according to present invention may comprise effective amount of cefprozil, an effective effervescent couple and additionally at least one excipient which is selected from a group comprising pharmaceutically acceptable amounts of binder, lubricant and sweetener.
  • effervescent formulation according to present invention comprises a mixture of components which gives off carbon dioxide gas upon contact with water.
  • This type of effervescent components are generally an acid or an acidic salt which may give off carbon dioxide gas upon contact with an alkali or alkali earth metal carbonate or hydrogen carbonate and aqueous solution.
  • Effervescent acid that is used in the effervescent formulation according to the present invention is selected from a group comprising pharmaceutically acceptable acids; especially organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, acetic acid, adipic acid, succinic acid, acetylsalicylic acid and/or acidic salts such as sodium citrate, sodium acetate, sodium dihydrogen phosphate, sodium acid pyrophosphate and sodium acid sulphite.
  • citric acid is used.
  • Alkali component that is used as effervescent base in the effervescent formulation according to the present invention can be selected from, but not limited with, sodium hydrogen carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
  • sodium hydrogen carbonate is used.
  • Effervescent formulations in accordance with the present invention comprises cefprozil, effervescent couple and additionally at least one excipient which is selected from a group comprising pharmaceutically acceptable amounts of binder, lubricant, sweetener and/or taste regulator, diluents, disintegrant, flavoring agent, coloring agent, surfactant, anti-foaming agent, humectants, acidic agent, basic agent.
  • Binder used in the effervescent formulation in accordance with the present invention can be selected from, but not limited with, a group comprising ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, methyl cellulose, polyvinylpyrrolidone and povidone.
  • a group comprising ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, methyl cellulose, polyvinylpyrrolidone and povidone.
  • polyvinylpyrrolidone is used.
  • Sweetener and/or taste regulator that can be used in effervescent formulations of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharin, saccharin sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose and xylitol or a combination thereof.
  • sodium chloride and/or sucralose is used.
  • Lubricant used in the effervescent formulation in accordance with the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
  • PEG 6000 is used.
  • Flavoring agents used in the present invention can be selected from a group comprising blackberry flavor, banana flavor, strawberry flavor, lemon flavor, orange flavor, peach flavor, vanilla flavor or similar natural fruits or might have the flavor of a natural herb.
  • cefprozil in the range of 50-5000 mg or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an amount equivalent to that can be used.
  • effervescent formulations in which cefprozil: binder ratio is in the range of 30:1 to 5:1, preferably 25:1 to 10:1, more preferably 20:1 to 12:1, are more stable and suitable for usage and transferring and can disperse more quickly.
  • the present invention is related to effervescent formulations wherein cefprozil: binder ratio is in the range of 30:1 to 5:1, preferably 25:1 to 10:1, more preferably 20:1 to 12:1.
  • the present invention is related to the effervescent formulations comprising cefprozil in an amount of 10-50%, effervescent couple in an amount of 50-90%, binder in an amount of 1-10 %, lubricant in an amount of 0.1-3 %, sweetener in an amount of 0.1-5 % by weight and at least one pharmaceutically acceptable excipient.
  • the present invention is related to the process for the preparation of pharmaceutical combinations comprising cefprozil as active agent and pharmaceutically acceptable excipients.
  • the present invention is related to the process comprising the steps of blending effervescent couple, binder and taste regulator and granulating them, obtaining the final mixture by adding cefprozil, lubricant and at least one pharmaceutically acceptable excipient into the obtained granules and preferably compressing the final mixture in the form of tablets.
  • the present invention is related to the use of effervescent formulations comprising cefprozil as active agent and pharmaceutically acceptable excipients for treatment of the infections caused by gram positive and gram negative bacteria.
  • EXAMPLE 1 Formulation and process for the preparation of effervescent tablet.
  • Formulation that can be used in the present invention is obtained by blending effervescent couple, taste regulator and binder and granulating them, adding cefprozil and sweetener to the obtained granules and adding flavoring agent and lubricant to the mixture and blending them.
  • the obtained mixture is compressed into tablets in the tablet pressing machine.

Abstract

Present invention relates to pharmaceutical formulations formulated in effervescent form comprising cefprozil active agent and the process for their preparations.

Description

EFFERVESCENT FORMULATIONS COMPRISING CEFPROZIL AS ACTIVE
AGENT
Present invention relates to pharmaceutical formulations formulated in effervescent form comprising cefprozil active agent and the process for their preparation. Background of the invention
Cefprozil, which is a second generation cephalosporin, was first disclosed in the patent numbered US4520022 and its chemical name is 8-[2-amino-2-(4-hydroxyphenyl)-acetyl] amino-7-oxo-4-prop-l-enyl-2-thia-6- azabicyclo [4.2.0]oct-4-ene-5-carboxylic acid. Cefprozil shown with Formula 1 is indicated for use in treatment of bronchitis, ear infections, skin infections and for treatment of other infections.
Formula I
In the prior art, the formulations comprising cefprozil as active agent are present in tablet, capsule or oral suspension forms. For example, the pharmaceutical formulations sold in the market under the tradename CEFZIL®, are present in tablet form comprising 250 and 500 mg cefprozil and in oral suspension form comprising 125 mg/5 ml and 250 mg/5 ml of cefprozil.
Tablet forms comprising 250 and 500 mg active agent in one dose become bigger in size when formulated with excipients. Accordingly, oral tablet and capsule dosage forms cause difficulty in swallowing especially for old people and children since they are difficult to swallow even though they are aclministered with water and have an unpleasant taste. This case impedes the drug intake and affects the efficacy of the treatment negatively. Moreover, bioavailability of oral dosage forms is far less than that of suspension forms.
However, suspension forms cause some problems such as; possibility to intake high and/or uncontrolled dose, the problems related to their physical and chemical stabilities after they are diluted with water and the difficulties in their usage and transferring. As is seen, new approaches are needed for obtaining formulations which are stable, which provides an efficient dosing and ease of use for especially pediatric and geriatric patients, which can disperse quickly and form a homogeneous suspension and have a high bioavailability. The inventors have surprisingly found that the problems in the prior art can be solved by the effervescent formulations that are prepared in accordance with the present invention.
Description of the invention
The present invention is related to effervescent formulations comprising cefprozil and process for the preparation of these formulations. Surprisingly, it is seen that effervescent forms formulated with the formulation comprising 10-50% of cefprozil, 50-90 % of effervescent couple, 1-10% of binder and 1-15% of at least one pharmaceutically acceptable excipient with respect to the total weight of unit dose, homogeneously and quickly disperse in water, provide effective dosing and ease of use, appeal to a wider patient profile and are stable and highly bioavailable. Accordingly, the first aspect of the present invention is effervescent formulations comprising 10-50% of cefprozil, 50-90% of effervescent couple, 1-10% of binder and 1-15% of at least one pharmaceutically acceptable excipient with respect to the total weight of unit dose.
"Effervescent formulations" term used in the text comprises effervescent tablets, effervescent granules and effervescent powders. Preferably effervescent formulations in accordance with the present invention are in the tablet form.
Effervescent powder, granule or tablet forms are more advantageous compared to the conventional forms due to the fact that they disperse quickly. Effervescent formulations disperse quickly and simultaneously and they disperse the active agents into the aqueous medium. Therefore, drug provides a homogeneous suspension by quickly dispersing in water and the bioavailability of the active agent increases considerably. Furthermore, since the effervescent forms are more stable due to the fact that they are in solid form, they have a longer shelf-life compared to suspension forms. Effervescent dosage forms that are suitable for single dose usage provides a controlled dose intake. Cefprozil that is used in the formulations formulated in effervescent form in accordance with the present invention can be present in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or as a combination thereof. Cefprozil that is used in the present invention can be present in one of the forms of monohydrate, dihydrate, trihydrate and/or anhydrous. Preferably, it is present in the form of monohydrate.
Effervescent formulations according to present invention may comprise effective amount of cefprozil, an effective effervescent couple and additionally at least one excipient which is selected from a group comprising pharmaceutically acceptable amounts of binder, lubricant and sweetener.
Accordingly, effervescent formulation according to present invention comprises a mixture of components which gives off carbon dioxide gas upon contact with water. This type of effervescent components are generally an acid or an acidic salt which may give off carbon dioxide gas upon contact with an alkali or alkali earth metal carbonate or hydrogen carbonate and aqueous solution.
Effervescent acid that is used in the effervescent formulation according to the present invention is selected from a group comprising pharmaceutically acceptable acids; especially organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, acetic acid, adipic acid, succinic acid, acetylsalicylic acid and/or acidic salts such as sodium citrate, sodium acetate, sodium dihydrogen phosphate, sodium acid pyrophosphate and sodium acid sulphite. Preferably, citric acid is used.
Alkali component that is used as effervescent base in the effervescent formulation according to the present invention can be selected from, but not limited with, sodium hydrogen carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate. Preferably, sodium hydrogen carbonate is used.
Effervescent formulations in accordance with the present invention comprises cefprozil, effervescent couple and additionally at least one excipient which is selected from a group comprising pharmaceutically acceptable amounts of binder, lubricant, sweetener and/or taste regulator, diluents, disintegrant, flavoring agent, coloring agent, surfactant, anti-foaming agent, humectants, acidic agent, basic agent.
Binder used in the effervescent formulation in accordance with the present invention can be selected from, but not limited with, a group comprising ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, methyl cellulose, polyvinylpyrrolidone and povidone. Preferably polyvinylpyrrolidone is used.
Sweetener and/or taste regulator that can be used in effervescent formulations of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharin, saccharin sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose and xylitol or a combination thereof. Preferably, sodium chloride and/or sucralose is used.
Lubricant used in the effervescent formulation in accordance with the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate. Preferably, PEG 6000 is used.
Flavoring agents used in the present invention can be selected from a group comprising blackberry flavor, banana flavor, strawberry flavor, lemon flavor, orange flavor, peach flavor, vanilla flavor or similar natural fruits or might have the flavor of a natural herb.
In effervescent formulations in accordance with the present invention, cefprozil in the range of 50-5000 mg or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an amount equivalent to that can be used.
Inventors have seen that effervescent formulations, in which cefprozil: binder ratio is in the range of 30:1 to 5:1, preferably 25:1 to 10:1, more preferably 20:1 to 12:1, are more stable and suitable for usage and transferring and can disperse more quickly. . In this aspect, the present invention is related to effervescent formulations wherein cefprozil: binder ratio is in the range of 30:1 to 5:1, preferably 25:1 to 10:1, more preferably 20:1 to 12:1.
In another aspect, the present invention is related to the effervescent formulations comprising cefprozil in an amount of 10-50%, effervescent couple in an amount of 50-90%, binder in an amount of 1-10 %, lubricant in an amount of 0.1-3 %, sweetener in an amount of 0.1-5 % by weight and at least one pharmaceutically acceptable excipient.
In another aspect, the present invention is related to the process for the preparation of pharmaceutical combinations comprising cefprozil as active agent and pharmaceutically acceptable excipients.
In this aspect, the present invention is related to the process comprising the steps of blending effervescent couple, binder and taste regulator and granulating them, obtaining the final mixture by adding cefprozil, lubricant and at least one pharmaceutically acceptable excipient into the obtained granules and preferably compressing the final mixture in the form of tablets. In another aspect the present invention is related to the use of effervescent formulations comprising cefprozil as active agent and pharmaceutically acceptable excipients for treatment of the infections caused by gram positive and gram negative bacteria.
Although it is not limited by these examples, efervescent formulations in accordance with the present invention can be prepared according to the following examples. EXAMPLE 1: Formulation and process for the preparation of effervescent tablet.
Formulation that can be used in the present invention is obtained by blending effervescent couple, taste regulator and binder and granulating them, adding cefprozil and sweetener to the obtained granules and adding flavoring agent and lubricant to the mixture and blending them. The obtained mixture is compressed into tablets in the tablet pressing machine.

Claims

1. A pharmaceutical composition formulated in effervescent form characterized in that said composition comprises 10-50% of cefprozil, 50-90% of effervescent couple, 1-10% of binder and 1-15% of at least one pharmaceutically acceptable excipient with respect to the total weight of the unit dose.
2. A pharmaceutical composition according to claim 1, wherein said composition comprises cefprozil and/or its salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystal and amorphous forms or in free form and/or a combination thereof.
3. A pharmaceutical composition according to claim 2, wherein cefprozil is present in one of the forms of monohydrate, dihydrate, trihydrate and/or in anhydrous form.
4. A pharmaceutical composition according to claim 3, wherein cefprozil is present in monohydrate form.
5. A pharmaceutical composition according to claim 1, wherein said composition is in the form of effervescent powder, granule or tablet.
6. A pharmaceutical composition according to claim 5, wherein said composition is in the form of effervescent tablet.
7. A pharmaceutical composition according to claim 1, wherein the amount of cefprozil in one unit dose is in the range of 50-1000 mg.
8. A pharmaceutical composition according to claim 1, wherein said formulation comprises as effervescent couple; an alkali component and an acid or an acidic salt which upon contact with aqueous solution gives off carbon dioxide.
9. A pharmaceutical formulation according to claim 8, wherein alkali component that is used as effervescent base is selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium hydrogen carbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
10. A pharmaceutical formulation according to claim 9, wherein sodium hydrogen carbonate is used as alkali component.
11. A pharmaceutical formulation according to claim 8, wherein effervescent acid is selected from a group pharmaceutically acceptable acids especially organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, acetic acid, adipic acid, succinic acid, acetylsalicylic acid and/or acidic salts such as sodium citrate, sodium acetate, sodium dihydrogen phosphate, sodium acid pyrophosphate and sodium acid sulphite.
12. A pharmaceutical formulation according to claim 11, wherein citric acid is used as effervescent acid.
13. A pharmaceutical formulation according to claim 1, wherein binder is selected from a group comprising ethyl cellulose, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, methyl cellulose, polyvinylpyrrolidone and povidone.
14. A pharmaceutical formulation according to claim 13, wherein polyvinylpyrrolidone is used as binder.
15. A pharmaceutical formulation according to claim 1, wherein said composition comprises cefprozil, effervescent couple and additionally at least one excipient which is selected from a group comprising pharmaceutically acceptable amounts of binder, lubricant, sweetener and/or taste regulator, diluents, disintegrant, flavoring agent, coloring agent, surfactant, anti-foaming agent, humectants, acidic agent, basic agent.
16. A pharmaceutical formulation according to claim 15, wherein lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
17. A pharmaceutical formulation according to claim 16, wherein PEG 6000 is used as lubricant.
18. A pharmaceutical formulation according to claim 15, wherein sweetener and/or taste regulator is selected from acesulfame, aspartame, dextrose, fructose, glycose, lactitol, maltitol, maltose, sorbitol, saccharin, saccharin sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose and xylitol or a combination thereof.
19. A pharmaceutical formulation according to claim 18, wherein sodium chloride and/or sucralose is used as sweetener and/or taste regulator.
20. A pharmaceutical formulation according to claim 15, wherein flavoring agent is selected from a group comprising blackberry flavor, banana flavor, strawberry flavor, lemon flavor, orange flavor, peach flavor, vanilla flavor or similar natural fruits or might have the flavor of a natural herb.
21. A pharmaceutical formulation according to claim 1, wherein cefprozil: binder ratio is in the range of 30: 1 and 5:1.
22. A pharmaceutical formulation according to claim 21, wherein cefprozil: binder ratio is in the range of 25:1 and 10:1.
23. A pharmaceutical formulation according to claim 22, wherein cefprozil: binder ratio is in the range of 20:1 and 12:1.
24. A pharmaceutical formulation according to claim 1, wherein said composition comprises cefprozil in an amount of 10-50%, effervescent couple in an amount of 50-90%, binder in an amount of 1-10 %, lubricant in an amount of 0.1-3 %, sweetener in an amount of 0.1-5
% by weight and at least one pharmaceutically acceptable excipient.
25. A process for the preparation of the pharmaceutical composition according to claims 1-24, wherein said process comprises the steps of blending effervescent couple, binder and taste regulator and granulating them, obtaining the final mixture by adding cefprozil, lubricant and at least one pharmaceutically acceptable excipient into the obtained granules.
26. A pharmaceutical composition according to claims 1-25, wherein said composition is used in the treatment of the infections caused by gram positive and gram negative bacteria.
EP11708946A 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent Withdrawn EP2528593A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00689A TR201000689A1 (en) 2010-01-29 2010-01-29 Solid dosage forms containing cefprozil.
PCT/TR2011/000036 WO2011093831A2 (en) 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent

Publications (1)

Publication Number Publication Date
EP2528593A2 true EP2528593A2 (en) 2012-12-05

Family

ID=44065360

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11708946A Withdrawn EP2528593A2 (en) 2010-01-29 2011-01-31 Effervescent formulations comprising cefprozil as active agent

Country Status (3)

Country Link
EP (1) EP2528593A2 (en)
TR (1) TR201000689A1 (en)
WO (2) WO2011093828A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658616A (en) * 2020-05-22 2020-09-15 广州白云山医药集团股份有限公司白云山制药总厂 Cefprozil dry suspension and preparation method thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357086A (en) * 2011-11-01 2012-02-22 上海理工大学 Cefprozil orally disintegrating tablets
WO2013109201A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising cefprozil and clavulanic acid
CN114886859A (en) * 2022-06-09 2022-08-12 哈尔滨凯程制药有限公司 Cefprozil granules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520022A (en) 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
CN100417383C (en) * 2006-03-07 2008-09-10 中国药科大学 Effervescent tablet containing cefixime and its preparing method
CN101032489B (en) * 2006-03-08 2011-06-15 上海秀新臣邦医药科技有限公司 Cefprozil dispersible table and the preparing method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011093831A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658616A (en) * 2020-05-22 2020-09-15 广州白云山医药集团股份有限公司白云山制药总厂 Cefprozil dry suspension and preparation method thereof
CN111658616B (en) * 2020-05-22 2022-03-15 广州白云山医药集团股份有限公司白云山制药总厂 Cefprozil dry suspension and preparation method thereof

Also Published As

Publication number Publication date
WO2011093828A2 (en) 2011-08-04
WO2011093831A2 (en) 2011-08-04
WO2011093828A3 (en) 2012-02-23
TR201000689A1 (en) 2011-08-22
WO2011093831A3 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
JP7216055B2 (en) Pharmaceutical composition
EP2528589B1 (en) Stable efervescent formulations comprising cefaclor
JP5235416B2 (en) Tetracycline metal complexes in solid dosage forms.
JP4740740B2 (en) Drug-containing particles and solid preparation containing the particles
WO2011093831A2 (en) Effervescent formulations comprising cefprozil as active agent
EP2566448B1 (en) Efervescent formulations comprising cefdinir
EP2563340A2 (en) Water soluble pharmaceutical composition
EP2566449B1 (en) Pharmaceutical compositions comprising ceftibuten
EP2515850B1 (en) Pharmaceutical compositions comprising cefdinir as an active agent
US20130129791A1 (en) Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
EP2566451B1 (en) Pharmaceutical compositions comprising cefditoren pivoxil
WO2011093829A1 (en) Effervescent formulations comprising cefixime and clavulanic acid as active agents
WO2011129792A1 (en) Water dispersible formulations comprising cefpodoxime proxetil
EP2046337A2 (en) Solid forms containing meloxicam with improved buccal taste and process for their preparation
EP2515858A1 (en) Pharmaceutical composition with high purity
EP2515859A1 (en) Rapidly dispersing effervescent formulation
EP2566450A2 (en) Pharmaceutical compositions comprising cefetamet
WO2013109230A1 (en) Pharmaceutical compositions comprising tadalafil
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
WO2011139250A2 (en) Water dispersible formulation
WO2013109201A1 (en) Pharmaceutical compositions comprising cefprozil and clavulanic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120820

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BILGIC, MAHMUT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140513